APP and Alzheimer disease: Significantly, a compound denoted as melatonin-trientine, covalently synthesized with melatonin and the metal ion chelator trientine, demonstrated the capacity to elevate the expression of IDE in a murine AD model, and decreased Aβ deposition and neuronal degeneration in the brains of the APP/Presenilin 1 mice [65].